INCY vs. RVMD: Who Wins the KRAS Battle?

INCY vs. RVMD: Who Wins the KRAS Battle? Prepared for: Unknown Publisher | Date: 31 Aug 2026

1. Executive snapshot • Both Incyte (INCY, $25.9 B m-cap, P/E ≈ 15.8x) and Revolution Medicines (RVMD, $43.8 B m-cap, negative earnings) are pursuing small-molecule KRAS inhibitors, but they start from very different financial foundations. INCY is a profitable, cash-rich mid-cap with no long-term debt; RVMD is a late-stage development company that is still pre-revenue and heavily reliant on external capital.

2. Dividend policy / return of capital • INCY has never paid a dividend and instead deploys free cash flow to share repurchases (≈ $758 M in 2024 and $2.0 B cumulative through 2025). (sec.gov) • RVMD does not pay a dividend and is unlikely to do so before reaching commercial revenue. The company raised ~$1.5 B in equity and $500 M of 0.50% convertible senior notes due 2033 in April 2026. (ir.revmed.com)

3. Balance-sheet leverage & maturity profile INCY • Cash & equivalents: $3.10 B; U.S.-gov’t debt securities: $0.48 B; No interest-bearing debt outstanding → net cash ≈ $3.6 B. (sec.gov) RVMD • Cash, equivalents & marketable securities: $2.0 B at 12-31-25. (ir.revmed.com) • New 0.50% convertible notes: $500 M, senior unsecured, due 2033; initial conversion price $198.80. (ir.revmed.com) • Pro-forma net cash ≈ $2.5 B after financings, but leverage will rise once spend accelerates.

4. Coverage & liquidity • INCY generated 2025 operating cash flow of $1.9 B and net income of $1.29 B, easily covering R&D and buybacks. (sec.gov) • RVMD burned ~$1.2 B cash in 2025 (R&D $987 M; net loss $1.1 B) and guides to 2026 GAAP opex $1.6-1.7 B. Cash runway ≈ 2+ years assuming similar burn plus $1.75 B of contingent Royalty Pharma capital. (ir.revmed.com)

5. Valuation snapshot (31 Aug 2026 close) INCY: P/E 15.8x, EV/EBITDA ≈ 10x (peer profitable SMID-cap biopharm median 18x). RVMD: no earnings; trades at 21x 2025 R&D spend or ~2.2× cash. Market is baking in multi-$-billion KRAS franchise success. (ir.revmed.com)

6. KRAS pipeline head-to-head INCY • INCB161734 – potent, selective oral KRAS G12D inhibitor; Phase 1 dose-escalation in PDAC showed no DLTs and early disease-control signals (data Sep 2025). (investor.incyte.com) • Strategy: first-in-class G12D monotherapy, then combinations (e.g., INCA33890 TGFβR2×PD-1 bispecific) per 2026 proxy statement. (investor.incyte.com) RVMD • Daraxonrasib (RMC-6236) – “RAS(ON)” multi-selective inhibitor (covers G12D/G12V/G12R, etc.); FDA granted Expanded Access April 2026 and AP story signals first-in-class survival benefit in pancreatic cancer. (apnews.com) • Elironrasib (RMC-6291, G12C), Zoldonrasib (RMC-9805, G12D) and RMC-5127 (G12V) all in Phase 1/2; multiple combo studies underway (Summit, Tango, BMS). (ir.revmed.com)

7. Key risks & red flags INCY • Patent cliff: core JAKAFI U.S. composition patent expires 2028. Loss of cash-cow royalties could compress FCF. (sec.gov) • Single-asset KRAS exposure; competitors (Amgen, Mirati/Pfizer, RVMD) may set bar for ORR/PFS before INCY’s G12D is registrational. RVMD • Execution risk: four parallel KRAS trials drive very high cash burn; any safety signal (e.g., on-target RAS toxicity) could stall entire platform. • Convert overhang: $500 M converts become in-the-money above $259/share (130% trigger) starting 3Q 26; potential dilution of ~12% if fully converted. (ir.revmed.com)

8. Open questions for management INCY • When will a pivotal study for INCB161734 start, and in which tumor type (PDAC vs. CRC)? • How does management plan to offset JAKAFI erosion post-2028? RVMD • What is the regulatory path for daraxonrasib—breakthrough therapy/accelerated approval based on Phase 2 PDAC data? • Will the company draw the remaining $1.75 B Royalty Pharma tranches, and at what milestones?

9. Bottom-line: who wins? Near-term (2026-28): RVMD is ahead clinically with a multi-selective KRAS candidate already under expanded access and broad Phase 2 program; INCY’s G12D program is at least a year behind. Medium-term (2028-30): Financial durability favors INCY—its positive cash flow can fund late-stage trials without dilution, whereas RVMD must execute flawlessly or return to capital markets. Investor lens: • GARP/quality investors may prefer INCY (profitability, optionality on KRAS). • High-beta oncology specialists may target RVMD for binary upside on first-in-class RAS(ON) data, accepting dilution/financing risk.

10. Verdict Clinically, RVMD currently “wins” the KRAS race; financially, INCY is the more resilient equity. Positioning a long INCY / speculative RVMD call-option pair could balance science upside with balance-sheet discipline.

For informational purposes only; not investment advice.